At the core of every AI coding agent is a technology called a large language model (LLM), which is a type of neural network ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

A steaming bowl of pho becomes the most vivid thing in your visual field – the clear amber broth, bright green herbs, ruby red sriracha swirls, and sunny yellow lime wedges appearing almost ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

After completing your single task (and taking a break to acknowledge your progress), you move to the next concrete action.

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

The leaked internal chat communications of the Black Basta ransomware group offer an unprecedented view into how cybercriminals operate, plan attacks, and ...